Induction therapy with linezolid/clarithromycin combination for <i><scp>M</scp>ycobacterium chelonae</i> skin infections in immunocompromised hosts

Parize, Perrine; Hamelin, A.; Véziris, Nicolas; Morand, P; Guillemain, R.; Lortholary, Olivier; Dupin, Nicolas

doi:10.1111/jdv.12965

Cited by 6 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can cause local cutaneous infections in immunocompetent patients, but infections are more frequently identified in patients taking immunosuppressive medications. Patients can develop painful subcutaneous nodules involving joints or soft tissue [ 2 ]. These skin nodules, as well as deeper and more disseminated infections, are usually from traumatic introduction.…”

Section: Discussionmentioning

confidence: 99%

“…Treatment generally involves two antibacterial agents, particularly in immunocompromised patients. Linezolid has been shown to be an effective second medication; however, its adverse effects of bone marrow suppression warrant close monitoring [ 2 ]. Once daily dosing of linezolid 600 mg has demonstrated a potential benefit of decreasing the risk of toxicity over a prolonged course of treatment.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sporotrichoid-Like Spread of Cutaneous Mycobacterium chelonae in an Immunocompromised Patient

Kemp

Govind

Jun

et al. 2017

Case Reports in Dermatological Medicine

View full text Add to dashboard Cite

Mycobacterium chelonae is a rapidly growing mycobacterium found in water and soil that can cause local cutaneous infections in immunocompetent hosts but more frequently affects immunocompromised patients. Typically, patients will present with painful subcutaneous nodules of the joints or soft tissues from traumatic inoculation. However, exhibiting a sporotrichoid-like pattern of these nodules is uncommon. Herein, we report a case of sporotrichoid-like distribution of cutaneous Mycobacterium chelonae in a patient with systemic lupus erythematosus on significant immunosuppressive medications. Clinicians treating immunocompromised patients should be cognizant of their propensity to develop unusual infections and atypical presentations.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Sporotrichoid-Like Spread of Cutaneous Mycobacterium chelonae in an Immunocompromised Patient

Kemp

Govind

Jun

et al. 2017

Case Reports in Dermatological Medicine

View full text Add to dashboard Cite

show abstract

“…Linezolid is an oxazolidinone antibiotic that binds to bacterial 23S ribosomal RNA of the 50S subunit to inhibit bacterial protein synthesis and has in vitro activity against most mycobacterial species [45][46][47]. Clinical outcomes data in humans are most readily available for Mabs and M. chelonae infections [27,28,48]. Linezolid is also considered an alternative treatment option for MAC [28].…”

Section: Linezolidmentioning

confidence: 99%

Contemporary Pharmacotherapies for Nontuberculosis Mycobacterial Infections: A Narrative Review

et al. 2023

View full text Add to dashboard Cite

Nontuberculous mycobacteria (NTM) are a group of atypical bacteria that may cause a spectrum of clinical manifestations, including pulmonary, musculoskeletal, skin and soft tissue, and cardiac infections. Antimycobacterial medication regimens for NTM infections require multiple agents with prolonged treatment courses and are often associated with poor tolerance in patients and suboptimal clinical outcomes. This review summarizes NTM pharmacotherapy, including treatment concepts, preferred medication regimens according to NTM species and site of infection, and emerging treatment methods for difficult-totreat species.

show abstract

“…Tissue biopsy and culture are the most sensitive diagnostic test [1] . For serious skin and soft tissue infections, 6-month combination therapy including a macrolide and a second agent based on antimicrobial susceptibility testing is recommended [2] . Surgical debridement is another important element of successful therapy.…”

mentioning

confidence: 99%

Multifocal ulceronecrotic skin lesions—A stigmatizing case

Bernier

Lapierre

El-Housseini

et al. 2017

IDCases

View full text Add to dashboard Cite

Mycobacterium chelonae is a rapidly growing nontuberculous mycobacteria, ubiquitous in the environment and mostly involved in skin, soft tissue and bone infections. An atypical, severe and multifocal dermatological manifestation of Mycobacterium chelonae infection in an immunocompetent patient is described here. The lesions completely resolved using a multidisciplinary approach. This case emphasizes the important aspects of diagnosis, antimicrobial and surgical management.

show abstract

Induction therapy with linezolid/clarithromycin combination for Mycobacterium chelonae skin infections in immunocompromised hosts

Abstract: We therefore suggest linezolid/clarithromycin combination as the initial therapeutic strategy for M. chelonae skin infections in immunocompromised patients.

Cited by 6 publications

References 21 publications

Sporotrichoid-Like Spread of Cutaneous Mycobacterium chelonae in an Immunocompromised Patient

Sporotrichoid-Like Spread of Cutaneous Mycobacterium chelonae in an Immunocompromised Patient

Contemporary Pharmacotherapies for Nontuberculosis Mycobacterial Infections: A Narrative Review

Multifocal ulceronecrotic skin lesions—A stigmatizing case

Contact Info

Product

Resources

About